No Apparent Alteration of F-18 FDG Biodistribution When Injected Shortly After Insulin GlargineNiederkohr, Ryan D., MD; Quon, Andrew, MDClinical Nuclear Medicine: April 2007 - Volume 32 - Issue 4 - p 302-303 doi: 10.1097/01.rlu.0000257273.55996.8b Interesting Image Buy Abstract Author InformationAuthors Article MetricsMetrics F-18 FDG PET scans acquired after insulin administration usually show prominent skeletal and cardiac muscle FDG uptake, which may hinder accurate scan interpretation. We performed an FDG PET/CT scan on a 25-year-old diabetic woman who received the long-acting insulin analog glargine (Lantus; Sanofi-Aventis) 3 hours before FDG injection. The scan showed no significant alteration of FDG biodistribution. Insulin glargine has no pronounced peak over 24 hours and is being used more frequently to create basal insulin level in patients with type 1 and type 2 diabetes. Our findings suggest that insulin glargine may not need to be withheld prior to PET scintigraphy. From the Division of Nuclear Medicine, Stanford University Medical Center, Stanford, CA. Received for publication October 16, 2006; accepted December 20, 2006. The authors report no conflict of interest with the material presented in this manuscript. Reprints: Ryan D. Niederkohr, MD, Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Drive, Room H-0101, Stanford, CA 94305-5281. E-mail: firstname.lastname@example.org. © 2007 Lippincott Williams & Wilkins, Inc.